Medical Device Success

DECEMBER 18, 2011

I sincerely hope all of you have had a productive and successful 2011. If you have struggled in 2011, let me know, perhaps I can share some ideas for success. The difference between Strategies and Tactics www.medicaldevicesuccess.com/2011/01/04/critical-the-difference-between-strategies-and-tactics/.

Medical 100

Medical Sales Marketing Consulting 100

World of DTC Marketing

AUGUST 19, 2022

Data from the Kaiser Family Foundation (KFF) shows that between 2011 and 2021, the average premiums for family coverage rose from $15,073 to $22,221—an increase of 47.4%. As the U.S. population health issues increase, the risk of insuring the average American goes up.

Healthcare 264

Healthcare Healthcare Insurance Competition 264

World of DTC Marketing

AUGUST 27, 2021

The FDA approved 309 new drugs between 2011 and 2018, 38 per year on average. More than 40 million patients are needed to meet the demand of currently enrolling trials. According to antidote.com. More than 18,000 clinical trials are actively recruiting patients in the U.S. In 2018, the FDA approved 59 new drugs – an all-time high.

Recruitment 195

Recruitment Patients FDA Medical 195

Medical Device Success

NOVEMBER 17, 2010

Then I ask you, “Do you have a formal written plan that articulates the strategies and tactics you will follow in 2011?” Write down the fact you will make a strategic plan for 2011 or the next 6 months…whatever. If you are driving a car, you know that it will take less time to follow the path of A to E and it will cost less in fuel.

Sales 100

Sales Medical Marketing Consulting 100

European Pharmaceutical Review

OCTOBER 17, 2024

World Allergy Organization (WAO) White Book on Allergy 2011-2012: Executive Summary. Finger Injection With High-Dose (1:1,000) Epinephrine: Does It Cause Finger Necrosis And Should It Be Treated? Hand (N Y). 2007; 2(1):5-11. Derived from IQVIA Claims Data, 2023. Casale TB, Ellis AK, Nowak-Wegrzyn A, et al.

Food and Drug Administration 121

Food and Drug Administration Medicine Food Side effects 121

European Pharmaceutical Review

AUGUST 23, 2022

To achieve this objective, the regulation amends Directive 2011/24/EU on the application of patients’ rights in cross?border Directive 2011/24/EU had the merit of drawing attention to the need for an appropriate and centralised assessment of health technologies but failed to ensure effective harmonisation on the issue. Lorgelly PK.,

Consulting 98

Consulting Medical Healthcare Healthcare 98

Pharmaceutical Technology

JUNE 19, 2023

Novartis and Incyte Corp’s Jakafi was the first FDA-approved drug for the treatment of myelofibrosis in November 2011. First-in-line treatment for myelofibrosis currently involves treatment with Jakafi (ruxolitinib) in combination with other drugs such as danazol.

Food and Drug Administration 98

Food and Drug Administration FDA Prescription Food 98

Pharmaceutical Commerce

NOVEMBER 13, 2023

Exparel was initially approved in 2011 for single-dose infiltration into a surgical site.

FDA 52

FDA 52

Pharmaceutical Technology

APRIL 7, 2023

Makena was approved by the FDA under the accelerated approval pathway in 2011 to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of spontaneous preterm birth. The decision was made after studies did not prove the effectiveness of the drug in preventing preterm birth.

Food and Drug Administration 97

Food and Drug Administration FDA Food Pharma 97

Pharmaceutical Technology

APRIL 7, 2023

Makena was approved by the FDA under the accelerated approval pathway in 2011 to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of spontaneous preterm birth. The decision was made after studies did not prove the effectiveness of the drug in preventing preterm birth.

Food and Drug Administration 95

Food and Drug Administration FDA Food Pharma 95

European Pharmaceutical Review

MARCH 1, 2024

MHRA confirmed that this new marketing authorisation was granted to Amgen Limited, as a line extension of the original marketing authorisation for XGEVA 120mg solution for injection, which was granted on 13 July 2011. The post New antibody drug formulation wins novel MHRA approval appeared first on European Pharmaceutical Review.

Medicine 97

Medicine Healthcare Healthcare Marketing 97

Legacy MEDSearch

MAY 3, 2023

Leadership includes Joy Celebre (recruiting since 1996, joined in 2008), Carolyn Jones (recruiting since 1995, joined in 2011), Arshad Alam (recruiting since 1995, joined 2017), John White (Talent Sourcing Manager, joined 2012), and Partner Chris Miclot, (joined 2012). “In

Recruitment 98

Recruitment Medical Management Media 98

pharmaphorum

JULY 6, 2022

A European Federation of Pharmaceutical Industries and Associations (EFPIA) report published earlier this year, for example, compared the timelines of six regulatory agencies between 2011 and 2020. It found the EMA “lagged behind” most, with a median approval time in 2020 of more than 400 days.

Safety 98

Safety FDA Medicine Patients 98

Pharmaceutical Technology

NOVEMBER 14, 2022

In August 2021, Saphnelo, a type 1 interferon receptor antibody, became the first lupus treatment to be approved since GSK’s Benlyta (belimumab) won a regulatory nod in 2011. MSCs and CAR-Ts for lupus. As per AstraZeneca's recent Q3 earnings, Saphnelo has yielded $69 million to date this year.

Side effects 144

Side effects Patients Manufacturing Safety 144

PM360

JUNE 29, 2022

The line from the 2011 Pixar “Cars” sequel (trust me, as a parent of two, I have seen it countless times) points to the practical implication for voice technology. “Everything is voice activated these days.”

Marketing 96

Marketing Healthcare Provider Prescription Patients 96

Sales Talent

FEBRUARY 7, 2020

Starting in 2011, Baby Boomers began retiring in mass. Future Sales Hiring. Looking to 2021 and beyond, there are two factors that will intensify the battle for sales talent. The first factor is the aging of the U.S. population. Compounding this is a falling birth rate. percent annually in the 1970s to just.4 4 percent in 2020.

Sales 130

Sales B2B Sales Recruitment Marketing 130

European Pharmaceutical Review

SEPTEMBER 22, 2022

11 have recently conducted an analysis of international HTA submissions from 2011-2019 to determine the acceptability of single arm clinical studies and ECs as part of the drug reimbursement process. 2011 May; 46(3): 399–424. Patel et al. FDA presentation. Available at: [link]. Multivariate Behav Res. doi: 1080/00273171.2011.568786.

Food and Drug Administration 122

Food and Drug Administration Patients Distribution FDA 122

European Pharmaceutical Review

SEPTEMBER 13, 2023

The new rules will repeal the 2011 Directive on late payments and will replace it with a Regulation. According to the EC, the recent SME performance report established that SME value added for 2023 is still forecast to stay at 3.6 This is compared to 1.8 percent for large enterprises, which is lower than its 2019 level.

Pharma 96

Pharma Competition Marketing Training 96

Copyright Clearance Center

OCTOBER 1, 2022

When Marybeth left the Copyright Office, we were privileged to welcome her to CCC’s Board where she was a Director for seven years from 2011-2017. She was a global thought and policy leader and a beloved mentor to many generations of copyright professionals and lawyers.

59

59

pharmaphorum

JANUARY 25, 2023

BMS’ lawsuit claims that Imjudo (tremelimumab) infringes two patents covering its own CTLA4 drug Yervoy (ipilimumab), which has been on the market since 2011 and is a key component of combination therapies for cancer with BMS’ PD-1 inhibitor Opdivo (nivolumab).

Marketing 52

Marketing FDA Sales Pharma 52

PM360

OCTOBER 25, 2022

The digital health sector has grown significantly during the past decade, with $2 billion invested in 2011 and $44 billion in 2021 by the global financial and corporate markets. In the shadow of the pandemic, tremendous investment poured into digital health. But in the past year, investors have been more selective in their decisions.

Marketing 98

Marketing Leads Healthcare Healthcare 98

Copyright Clearance Center

MAY 22, 2024

Serials has been fully digitised and is openly accessible at serials.uksg.org.

40

40

Medical Device Success

JANUARY 4, 2011

The party is over and we are back at the office confronted by 2011. Reading time: 4 – 6 minutes. HAPPY NEW YEAR! Strategy without tactics is the slowest route to victory. Tactics without strategy is the noise before defeat.” From The Art of War by Sun Tzu. This is the eighth post in the series on Strategic Planning.

Medical 100

Medical Consulting 100

Pharmaceutical Technology

NOVEMBER 3, 2022

A Quantitative View on Award Criteria in Tenders in the EU5 from 2011 to 2020 , Genane C, Trenti S In-Person and Virtual Poster Session 3 Date: Tuesday 8 November 2022 Poster Session Time: 10:00–13:15 HPR150: P&R Policies and Macro-Trends Pertinent to CGTs: Where Are the Main Barriers and Who Leads the Efforts to a Greater Access?

Pharma 52

Pharma Leads Medical Pharmaceutical 52

pharmaphorum

NOVEMBER 25, 2022

He became CEO in 2011, as the company moved from purely consulting to developing forecast models, and has continued to evolve the business, using innovative technology to drive efficiencies for clients’ processes. About the author. David James has a long history within global product forecasting and consulting and co-launched J+D in 2005.

Marketing 122

Marketing Patients Consulting Sales 122

Pharma Marketing Network

MARCH 25, 2022

February 2019. Accessed March 12, 2022. National Alliance for Caregiving. Public Health. Accessed March 15, 2022. American Psychological Association. Caregiving Facts. Accessed February 28, 2022. Centers for Disease Control and Prevention. Caregiving for family and friends — a public health issue. Accessed March 12, 2022.

Pharma 98

Pharma Training Education Transportation 98

pharmaphorum

FEBRUARY 23, 2016

According to the European Commission and NIHR Clinical Research Network, between 2007 and 2011, delays for launching clinical trials rose by 90%. And with approximately one third of the clinical trial timeline spent in patient recruitment, delays in launching clinical trials will increase costs and drain resources.

Patients 52

Patients Recruitment Management Media 52

European Pharmaceutical Review

JUNE 6, 2025

He co-founded Pluriomics/Ncardia in 2011 and invented its core technologies. About the author Stefan Braam is the co-founder and Chief Technical Officer of Cellistic and its affiliate company, Ncardia. Stefan has over a decade of experience in stem cell technology, product development and general management.

Engineering 52

Engineering Manufacturing Media Distribution 52

pharmaphorum

NOVEMBER 6, 2022

Here is a long list of biotechs in the AI antibody space: Company name. Disclosed Funding. Vancouver, Canada. Washington, US. Cardiff, Wales. BigHat Biosciences. California,US. ImmunitoAI. Bangalore, India. RubrYc Therapeutics. California, US.

Biopharma 123

Biopharma Pharma Training Leads 123

Healthcare Success

JANUARY 25, 2023

The rate of injuries from violent attacks against medical professionals grew by 63% from 2011 to 2018. To be clear, workplace violence experienced by healthcare workers predates the pandemic. However, these numbers escalated in 2020, along with the COVID-19 pandemic. Why are people so angry and rude? How did we get here?

Patients 105

Patients Healthcare Healthcare Management 105

Impetus Digital

SEPTEMBER 21, 2022

He started his career in banking and business line management before going through the MBA program at Berkeley in 2011. Marius Rus Founder Marius Rus is a finance and strategy expert turned healthcare entrepreneur.

Professional Services 52

Professional Services Consulting Healthcare Provider Healthcare 52

Legacy MEDSearch

JANUARY 13, 2023

Headquartered in Boca Raton, Florida, Hip Innovation Technology was formed in 2011 to provide market-leading orthopedic device solutions that advance the quality of life and quality of care for patients. About Hip Innovation Technology, LLC.

FDA 98

FDA Safety Recruitment Patients 98

pharmaphorum

SEPTEMBER 30, 2022

Although the sticker shock that was at first associated with Yervoy (ipilimumab) in 2011 – in the early days of immuno-oncology monoclonal antibodies – has fallen by the wayside, especially in light of CAR-Ts and other “one and done” cell and gene therapies, the field of non-orphan oncology remains a target for cost savings by payers.

Consulting 98

Consulting Marketing Pharma Manufacturing 98

pharmaphorum

OCTOBER 9, 2022

Chowiria was previously chairman and CBO at Nektar 2011 when it was trying to build a business in respiratory therapeutics including a now-defunct inhaled formulation of insulin. One link between the two companies lies in PureTech’s president and chief business officer Bharat Chowiria, note analysts at Mizuho.

Leads 59

Leads Healthcare Healthcare 59

Pharmaceutical Technology

JUNE 22, 2008

The bill mostly relates to pharmaceutical companies, and the new amendments due to come in place in 2011 could impose further regulation. The industry already spends an estimated $25bn a year marketing products to medical professionals, ranging from offering a game of golf to consulting fees. .”

Physicians 40

Physicians Doctors Pharmaceutical Consulting 40

Integrity Solutions

JUNE 24, 2024

Watt shared that Phillips was the Texans coach who “stood up on the table” to advocate taking him in the first round of the 2011 NFL Draft. In fact, I remember that moment well—I’d been there too.

Sales 171

Sales Sales Management Management Sales tools 171

European Pharmaceutical Review

JULY 4, 2024

Herbal medicines placed on the market since April 2011 must have either a traditional herbal registration (THR) or a Marketing Authorisation (MA). 6 Thus, it is critical to ensure the consistency of therapeutic effect across batches (see box). 10,12 The THR scheme is also limited to products used for oral or external use and/or inhalation.

Marketing 103

Marketing Food and Drug Administration Medicine Prescription 103